Cambrex (CBM) Return on Equity ROE from the third quarter 2019 to third quarter 2018 and annually, average high and low, overall ranking from Sep 30 2019 to Sep 30 2018 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Cambrex Corp  (CBM)

Cambrex's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Cambrex in the third quarter 2019?
Cambrex Corp achieved a return on average equity (ROE) of 5.52 % in its third quarter 2019, which is below Cambrex's average return on equity, which stands at 22.72%.

ROE decreased relative to the period ending , due to the decline in net income.

Within the Major Pharmaceutical Preparations industry 55 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2019 from 1095 to 1819.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2019)
III. Quarter		 (Jun 30 2019)
II. Quarter		 (Mar 31 2019)
I. Quarter		 (Dec 31 2018)
IV. Quarter		 (Sep 30 2018)
III. Quarter
Y / Y Equity Change 2.52 % 8.54 % 11.23 % 19.98 % -
Y / Y Net Income Change -64.29 % -61.36 % -56.73 % -96.99 % 54.54 %
Net Income (TTM) in Millions 37 54 79 92 131
Return On Equity (TTM) 5.52 % 8.15 % 12.14 % 14.62 % 21.73 %
CBM's Total Ranking # 1819 # 1095 # 0 # 969 # 568
Equity (TTM) in Millions 676 677 659 654 659
Seq. Equity Change -0.1 % 2.62 % 0.86 % -0.84 % 5.77 %
Seq. Net Income Change -38.88 % 50.04 % 758.83 % -95.47 % -33.87 %

Back to CBM Management Effectiveness >> CBM's 5 Years Annual ROE >> Compare CBM ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 56
Sector # 153
Overall # 1819

Return On Equity Statistics
High Average Low
48.4 %
22.72 %
5.52 %
(Dec 31 2012)   (Sep 30 2019)





CBM Annual Return On Equity (Dec 31 2018)
2018		 (Dec 31 2017)
2017		 (Dec 31 2016)
2016		 (Dec 31 2015)
2015		 (Dec 31 2014)
2014
Total Equity in Millions 654 545 405 311 251
Y / Y Equity Change 19.98 % 34.39 % 30.43 % 23.73 % 19.51 %
Net Income in Millions 92 102 82 57 57
Y / Y Net Income Change -9.79 % 25.43 % 42.75 % -0.15 % 121.12 %
Return On Equity 14.14 % 18.8 % 20.15 % 18.41 % 22.81 %

Back to CBM Management Effectiveness >> CBM's 5 Years Annual ROE >> Compare CBM ROE to its Competitors




Annual Roe Comment
In 2018 ROE decreased compared to the previous year to 14.14 %, due to deterioration of net income.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CBM's' Return on Equity at Yahoo Finance
CBM's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CBM's Competitors
Subscribers only: Roe for Cambrex's Suppliers
Subscribers only: Return On Equity for CBM's Customers




Companies with similar Return On Equity at Sep 30 2019, within Healthcare Sector ROE
Eagle Pharmaceuticals inc   15.14 %
Alexion Pharmaceuticals Inc   14.93 %
Edesa Biotech Inc   14.89 %
Utah Medical Products Inc  14.88 %
Medpace Holdings Inc   14.53 %
Pacific Health Care Organization Inc  14.45 %
Quest Diagnostics Inc  14.33 %
Lemaitre Vascular Inc   14.25 %
Omnova Solutions Inc  14.08 %
Henry Schein Inc   13.93 %
Universal Health Services Inc   13.54 %
The Cooper Companies Inc   13.25 %
Tivity Health Inc   13.22 %
Meridian Bioscience Inc   13.18 %
Ufp Technologies Inc   12.45 %
Gilead Sciences Inc   12.30 %
Boston Scientific Corporation  12.15 %
Amphastar Pharmaceuticals Inc   11.83 %
Globus Medical Inc   11.60 %
Anika Therapeutics Inc   11.59 %
Heartbeam Inc   11.44 %
Electromed Inc   11.43 %
Enanta Pharmaceuticals Inc  10.66 %
Abbott Laboratories  10.47 %
Angiodynamics Inc   10.41 %
Penumbra Inc  9.92 %
Inogen Inc   9.89 %
Neogen Corporation  9.62 %
National Healthcare Corp  9.60 %
Hill rom Holdings Inc   9.59 %

Date modified: 2026-09-08T15:09:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.